Scribe Therapeutics Inc. Common Stock (NASDAQ:SCTX) — Market Cap & Net Worth
Market Cap & Net Worth: Scribe Therapeutics Inc. Common Stock (SCTX)
Scribe Therapeutics Inc. Common Stock (NASDAQ:SCTX) has a market capitalization of $391.32 Million ($391.32 Million) as of October 13, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13592 globally and #3263 in its home market, demonstrating a 23.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scribe Therapeutics Inc. Common Stock's stock price $20.67 by its total outstanding shares 18931680 (18.93 Million).
Scribe Therapeutics Inc. Common Stock Market Cap History: 2026 to 2026
Scribe Therapeutics Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $391.32 Million to $391.32 Million (0.00% CAGR). Check SCTX stock price and chart for real-time trading data and today's change.
Scribe Therapeutics Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scribe Therapeutics Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Scribe Therapeutics Inc. Common Stock cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SCTX by Market Capitalization
Companies near Scribe Therapeutics Inc. Common Stock in the global market cap rankings as of October 13, 2026. See net asset quality index of Scribe Therapeutics Inc. Common Stock to understand what proportion of total assets are financed by equity.
Key companies related to Scribe Therapeutics Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $128.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #446 globally with a market cap of $63.44 Billion USD ( AU$89.66 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.50 Billion | $507.00 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $762.81 |
| #446 | CSL Ltd | AU:CSL | $63.44 Billion | AU$184.81 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $213.74 |
Scribe Therapeutics Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Scribe Therapeutics Inc. Common Stock's market cap moved from $391.32 Million to $ 391.32 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $391.32 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 13th, 2026 the market cap of Scribe Therapeutics Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $391.32 Million USD |
| MoneyControl | $391.32 Million USD |
| MarketWatch | $391.32 Million USD |
| marketcap.company | $391.32 Million USD |
| Reuters | $391.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more